Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04951154 · ClinicalTrials.gov registry record
A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 33
- Enrollment target
- 2
- Study locations
NCT04951154: Completed study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.
NCT04951154 is a study of Carcinoma, Non-Small Cell Lung that has completed, run by Janssen Research & Development. The registered enrollment target is 33 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04951154, a study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess spontaneous residual viable tumor cells (RVT) in the surgically resected tumor (Non-small cell lung cancer \[NSCLC\]).
Primary Outcome
Percent of RVT cells at the time of NSCLC resection will be reported.
Conditions Studied
Interventions
- OTHER Blood Sample
- OTHER Bronchoscopic Biopsy
Study Locations (2)
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2023-05-15 |
What the finished NCT04951154 record still lists
NCT04951154 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Blood Sample is the first listed.
NCT04951154 reports a single indexed study location in District of Columbia, New York.
Frequently Asked Questions
What is clinical trial NCT04951154 about?
NCT04951154 is a clinical study titled "A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer". The purpose of this study is to assess spontaneous residual viable tumor cells (RVT) in the surgically resected tumor (Non-small cell lung cancer \[NSCLC\]).
What is the current status of trial NCT04951154?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2022-03-28. Estimated completion is 2023-05-15.
What conditions does trial NCT04951154 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT04951154?
The interventions under investigation include: Blood Sample (OTHER), Bronchoscopic Biopsy (OTHER).
Who is sponsoring clinical trial NCT04951154?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04951154 being conducted?
This trial has 2 study locations across District of Columbia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04951154's enrollment target sits among peer trials
33 108th of 130 higher than 23 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI